Elicio Therapeutics (ELTX) Income towards Parent Company (2020 - 2026)
Elicio Therapeutics posted quarterly Income towards Parent Company of -$10.9 million for Q1 2026, down 1.4% year-on-year from -$11.0 million in Q1 2025, and down 18.23% on a QoQ basis from -$9.2 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Income towards Parent Company data on file, last reported at -$10.9 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 1.4% year-over-year to -$10.9 million; the trailing twelve-month figure through Mar 2026 stood at -$38.4 million (up 15.64% YoY), and the FY2025 full-year result was -$38.8 million, up 14.51% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$10.9 million, down from -$9.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$6.0 million in Q4 2022 and bottomed at -$14.5 million in Q1 2022.
- The 5-year median for Income towards Parent Company is -$10.1 million (2025), against an average of -$9.7 million.
- Peak annual rise in Income towards Parent Company reached 59.99% in 2022, while the deepest fall reached 140.99% in 2022.
- A 5-year view of Income towards Parent Company shows it stood at -$6.0 million in 2022, then slumped by 55.37% to -$9.3 million in 2023, then sank by 47.12% to -$13.7 million in 2024, then surged by 33.05% to -$9.2 million in 2025, then declined by 18.23% to -$10.9 million in 2026.
- The last three Income towards Parent Company figures came in at -$10.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.85 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -8.27 Mn |
| Jun 30, 2025 | -10.12 Mn |
| Mar 31, 2025 | -10.70 Mn |
| Dec 31, 2024 | -13.71 Mn |
| Sep 30, 2024 | -10.30 Mn |
| Jun 30, 2024 | -10.84 Mn |
| Mar 31, 2024 | -10.13 Mn |
| Dec 31, 2023 | -9.32 Mn |
| Sep 30, 2023 | -10.53 Mn |
| Jun 30, 2023 | -8.45 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Dec 31, 2022 | -6.00 Mn |
| Sep 30, 2022 | -6.84 Mn |
| Jun 30, 2022 | -7.30 Mn |
| Mar 31, 2022 | -14.49 Mn |
| Dec 31, 2021 | 14.63 Mn |
| Sep 30, 2021 | -15.76 Mn |
| Jun 30, 2021 | -18.24 Mn |
| Mar 31, 2021 | -19.94 Mn |
| Dec 31, 2020 | -13.85 Mn |
| Sep 30, 2020 | -11.59 Mn |
| Jun 30, 2020 | -17.27 Mn |
| Mar 31, 2020 | -12.57 Mn |